Saturday, March 21, 2009 2:19:46 PM
--------------------------------------------------------------------------------
20-Mar-2009
Other Events
Item 8.01 Other Events
Sovereign Exploration Associates International, Inc. (the "Company") has filed a Form 15 today with the Securities and Exchange Commission ("SEC") to voluntarily deregister its common stock. The Company is eligible to deregister because it has fewer than 300 holders of record of its common stock. In filing the Form 15, the Company's obligations to file certain reports and forms with the SEC, including Forms 10-K, 10-Q and 8-K, are immediately suspended. The Company expects that deregistration of its common stock will become effective within 90 days.
The Company is deregistering because it believes that the incremental cost of compliance with the Sarbanes-Oxley Act of 2002 and other public company reporting requirements does not provide a discernable benefit to the Company and is not in the best interests of its shareholders. Factors influencing the Company's decision include the following:
- The high accounting, legal and administrative costs of preparing and filing periodic reports and other filings with the SEC in comparison to the size of the Company.
- The need for senior management of the Company to devote more time to the business of the Company.
- The need to maintain the confidentiality of sensitive business information that would otherwise require SEC disclosure.
- The already limited trading in the Company's common stock..
- The fact that current trading prices of the common stock make it unlikely that the Company could effectively use its common stock to compensate employees, raise capital or make acquisitions.
As a result of this action, the Company's common stock will cease to be eligible to be traded on the Over-the-Counter Bulletin Board. The Company's securities will continue to be quoted on the Pink Sheets, but the Company can make no assurance that any broker will continue to make a market in the Company's common stock.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM